Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...
14d
Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference
Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...
Fast-tracked psychedelics hit a wall: why the FDA’s pause on psilocybin is an important check to ensure safety, rigor, and ...
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...
Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other ...
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results